Haploidentical peripheral blood stem cell infusion in combination with chemotherapy for acute myeloid leukaemia in elderly patients

• Published in: Internal medicine journal Vol. 44; no. 10; pp. 1038 - 1040
• Main Authors: Bishop, D. C., Johnston, A. J., Kwan, J. M. W., Antonenas, V., Gottlieb, D. J.
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.10.2014
• Subjects: acute myeloid leukaemia; adoptive cellular immunotherapy; Aged; Antimetabolites, Antineoplastic - administration & dosage; antineoplastic combined chemotherapy protocol/therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Cytarabine - administration & dosage; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute - blood; Leukemia, Myeloid, Acute - drug therapy; Male; Mitoxantrone - administration & dosage; Prognosis; Prospective Studies; Treatment Outcome; aged; hematopoietic stem cell transplantation; adoptive cellular immunotherapy; acute myeloid leukaemia; antineoplastic combined chemotherapy protocol/therapeutic use
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.12551

Elderly patients with acute myeloid leukaemia (AML) have a poor prognosis with standard chemotherapy. Two elderly AML patients treated with infusion of family‐derived partially human leukocyte antigen (HLA)‐matched peripheral blood stem cells following each cycle of chemotherapy entered morphological complete remission without graft versus host disease or major toxicity. Our results support this as a non‐toxic approach for inducing a graft versus leukaemia effect in patients not suitable for allogeneic transplantation. Additional resources required for donor assessment and harvest may be reduced by using banked partially HLA‐matched mononuclear cells from unrelated donors.